Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis

Dinara Guseinova, Alessandro Consolaro, Lucia Trail, Cristina Ferrari, Angela Pistorio, Nicolino Ruperto, Antonella Buoncompagni, Clarissa Pilkington, Susan Maillard, Sheila K. Oliveira, Flavio Sztajnbok, Ruben Cuttica, Fabrizia Corona, Maria Martha Katsicas, Ricardo Russo, Virginia Ferriani, Ruben Burgos-Vargas, Eunice Solis-Vallejo, Marcia Bandeira, Vicente BacaClaudia Saad-Magalhaes, Clovis A. Silva, Roberto Barcellona, Luciana Breda, Rolando Cimaz, Romina Gallizzi, Rosaria Garozzo, Silvana Martino, Antonella Meini, Achille Stabile, Alberto Martini, Angelo Ravelli

Research output: Contribution to journalArticlepeer-review


Objective: To compare the demographic features, presenting manifestations, diagnostic investigations, disease course, and drug therapies of children with juvenile dermatomyositis (JDM) followed in Europe and Latin America. Methods: Patients were inception cohorts seen between 1980 and 2004 in 27 paediatric rheumatology centres. The following information was collected through the review of patient charts: sex; age at disease onset; date of disease onset and diagnosis; onset type; presenting clinical features; diagnostic investigations; course type; and medications received during disease course. Results: Four hundred and ninety patients (65.5% females, mean onset age 7.0 years, mean disease duration 7.7 years) were included. Disease presentation was acute or insidious in 57.1% and 42.9% of the patients, respectively. The course type was monophasic in 41.3% of patients and chronic polycyclic or continuous in 58.6% of patients. The more common presenting manifestations were muscle weakness (84.9%), Gottron's papules (72.9%), heliotrope rash (62%), and malar rash (56.7%). Overall, the demographic and clinical features of the 2 continental cohorts were comparable. European patients received more frequently high-dose intravenous methylprednisolone, cyclosporine, cyclophosphamide, and azathioprine, while methotrexate and antimalarials medications were used more commonly by Latin American physicians. Conclusion: The demographic and clinical characteristics of JDM are similar in European and Latin American patients. We found, however, several differences in the use of medications between European and Latin American paediatric rheumatologists.

Original languageEnglish
Pages (from-to)117-124
Number of pages8
JournalClinical and Experimental Rheumatology
Issue number1
Publication statusPublished - Jan 2011


  • Clinical features
  • Disease course
  • Drug therapy
  • Juvenile dermatomyositis
  • Onset manifestations

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis'. Together they form a unique fingerprint.

Cite this